{"id":3429,"date":"2025-03-31T12:19:41","date_gmt":"2025-03-31T09:19:41","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=3429"},"modified":"2025-11-03T20:22:47","modified_gmt":"2025-11-03T17:22:47","slug":"exon-51-skipping-therapies-dmd","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/exon-51-skipping-therapies-dmd\/","title":{"rendered":"Duchenne Musk\u00fcler Distrofi Tedavisinde Yakla\u015fan Ekzon 51 Atlama Terapileri"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Duchenne Ekzon 51 atlama terapileri, Duchenne kas distrofisi (DMD) i\u00e7in sorumlu olan genetik mutasyonu ele almay\u0131 ama\u00e7layan yenilik\u00e7i tedavilerdir. Distrofin genindeki ekzon 51&#039;i atlayarak, bu terapiler distrofin proteininin daha k\u0131sa, i\u015flevsel bir versiyonunu \u00fcretmeye yard\u0131mc\u0131 olur, potansiyel olarak hastal\u0131\u011f\u0131n ilerlemesini yava\u015flat\u0131r ve hastalar\u0131n ya\u015fam kalitesini iyile\u015ftirir. Bu son teknoloji yakla\u015f\u0131m, kas fonksiyonunu geli\u015ftirmeye ve hareketlili\u011fi uzatmaya odaklanarak DMD hastalar\u0131 i\u00e7in umut sunar.<\/p>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>\u0130\u00e7indekiler<\/h2><nav><ul><li><a href=\"#about-duchenne\">Duchenne Hakk\u0131nda<\/a><\/li><li><a href=\"#exon-51-skipping-therapies\">Ekzon 51 Atlama Terapileri<\/a><\/li><li><a href=\"#what-is-exon-51-skipping\">Ekzon 51 Atlamas\u0131 Nedir?<\/a><\/li><li><a href=\"#fda-approved-exon-51-skipping-therapies\">FDA Onayl\u0131 Ekzon 51 Atlama Terapileri<\/a><ul><li><a href=\"#exondys-51-eteplirsen\">EXONDYS 51 (eteplirsen)<\/a><\/li><\/ul><\/li><li><a href=\"#which-mutations-are-amenable-to-exon-45-skipping\">Ekzon 51 Atlamaya Uygun Delesyonlar<\/a><\/li><li><a href=\"#clinical-trials-for-exon-51-skipping-therapies\">Ekzon 51 Atlama Terapileri i\u00e7in Klinik Denemeler<\/a><ul><li><a href=\"#dyne-therapeutics-dyne-251-exon-51\">Dyne Therapeutics \u2013 DYNE-251<\/a><\/li><li><a href=\"#jiao-tong-university-le-051\">Jiao Tong \u00dcniversitesi \u2013 LE051<\/a><\/li><li><a href=\"#bio-marin-pharmaceutical-bmn-351\">BioMarin \u0130la\u00e7 \u2013 BMN 351<\/a><\/li><li><a href=\"#entrada-therapeutics\">Entrada Therapeutics \u2013 G\u0130R\u0130\u015e-601-51<\/a><\/li><li><a href=\"#nippon-shinyaku-ns-051-ncnp-04\">Nippon Shinyaku \u2013 NS-051\/NCNP-04<\/a><\/li><\/ul><\/li><li><a href=\"#conclusion\">Sonu\u00e7<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"about-duchenne\">Duchenne Hakk\u0131nda<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Duchenne kas distrofisi (DMD), \u00f6ncelikle erkek \u00e7ocuklar\u0131n\u0131 etkileyen ve ilerleyici kas g\u00fc\u00e7s\u00fczl\u00fc\u011f\u00fcne, hareket kabiliyetinin kayb\u0131na ve sonunda solunum ve kalp komplikasyonlar\u0131na yol a\u00e7an ciddi bir genetik bozukluktur. DMD, kas h\u00fccre zarlar\u0131n\u0131 stabilize eden kritik bir protein olan distrofin kodlayan DMD genindeki mutasyonlardan kaynaklan\u0131r. Distrofin olmadan, kas lifleri kas\u0131lma s\u0131ras\u0131nda hasara daha yatk\u0131nd\u0131r ve bu da kas dejenerasyonuna ve DMD&#039;nin belirgin semptomlar\u0131na yol a\u00e7ar.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"exon-51-skipping-therapies\">Ekzon 51 Atlama Terapileri<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">DMD&#039;deki ana genetik mutasyon, DMD genindeki belirli ekzonlar\u0131n silinmesidir ve bu da i\u015flevsel distrofin \u00fcretimini bozar. DMD&#039;yi tedavi etme yakla\u015f\u0131mlar\u0131ndan biri, genin kusurlu k\u0131s\u0131mlar\u0131n\u0131 atlayarak kesilmi\u015f ancak k\u0131smen i\u015flevsel bir distrofin proteininin \u00fcretilmesine izin vermeyi ama\u00e7layan bir tedavi stratejisi olan ekzon atlamad\u0131r. Ekzon 51 atlama, en \u00e7ok \u00e7al\u0131\u015f\u0131lan ekzon atlama terapilerinden biridir ve \u00f6nemli bir DMD hasta alt grubuna umut sunmaktad\u0131r. (<a href=\"https:\/\/dmdwarrior.com\/tr\/what-is-exon-skipping-and-how-does-it-work\/\" data-type=\"post\" data-id=\"1445\">Ekzon Atlama Nedir?<\/a>)<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"what-is-exon-51-skipping\">Ekzon 51 Atlamas\u0131 Nedir?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">DMD geni 79 ekzondan olu\u015fur ve bu gendeki mutasyonlar genellikle belirli eksonlar\u0131n silinmesini i\u00e7erir. Bu silinmeler genellikle distrofin \u00fcretimini engelleyen bir \u00e7er\u00e7eve kaymas\u0131na neden olur. Ekzon 51 atlama, mutasyona u\u011fram\u0131\u015f ekzonu maskelemek ve RNA'n\u0131n ekleme i\u015flemi s\u0131ras\u0131nda o ekzonun \"atlanmas\u0131n\u0131\" te\u015fvik etmek i\u00e7in antisens oligon\u00fckleotidler (ASO'lar) kullanmay\u0131 i\u00e7erir. Ekzon 51 atlanarak, a\u015fa\u011f\u0131 ak\u0131\u015f eksonlar\u0131 bir araya getirilebilir, okuma \u00e7er\u00e7evesi geri y\u00fcklenir ve daha k\u0131sa ama i\u015flevsel bir distrofin formunun \u00fcretilmesine izin verilir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu strateji, normal distrofin eksikli\u011fini bir nebze telafi edebilen, hastal\u0131\u011f\u0131n ilerlemesini azaltabilen ve ekzon 51 atlamaya uygun delesyonlar\u0131 olan hastalarda kas fonksiyonunu iyile\u015ftirebilen i\u015flevsel bir distrofin proteinini geri kazand\u0131rmay\u0131 ama\u00e7lamaktad\u0131r. (Daha Fazlas\u0131n\u0131 Okuyun: <a href=\"https:\/\/dmdwarrior.com\/tr\/what-is-exon-deletion-in-duchenne-muscular-dystrophy-dmd\/\" target=\"_blank\" rel=\"noreferrer noopener\">DMD&#039;de Ekzon Delesyonu Nedir?<\/a>)<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"fda-approved-exon-51-skipping-therapies\">FDA Onayl\u0131 Ekzon 51 Atlama Terapileri<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"exondys-51-eteplirsen\">EXONDYS 51 (eteplirsen)<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">EXONDYS 51 (eteplirsen), distrofin geninde do\u011frulanm\u0131\u015f bir genetik mutasyonu olan ve ekzon 51&#039;i atlayarak tedavi edilebilen hastalar i\u00e7in ilk FDA onayl\u0131 Duchenne kas distrofisi tedavisidir. Baz\u0131 hastalarda, v\u00fccudun distrofin proteininin daha k\u0131sa bir formunu \u00fcretmesine yard\u0131mc\u0131 olur. (Daha Fazla Bilgi Edinin: <a href=\"https:\/\/dmdwarrior.com\/tr\/frequently-asked-questions-about-eteplirsen-exondys-51-for-dmd-treatment\/\" data-type=\"post\" data-id=\"2303\">Eteplirsen<\/a>)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">EXONDYS 51 (eteplirsen) Avrupa \u0130la\u00e7 Ajans\u0131 taraf\u0131ndan onaylanmam\u0131\u015ft\u0131r.<a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/exondys\" target=\"_blank\" rel=\"noopener\">EMA<\/a>)<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"which-mutations-are-amenable-to-exon-45-skipping\">Ekzon 51 Atlamaya Uygun Delesyonlar<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Ekzon 51 atlama, a\u015fa\u011f\u0131da g\u00f6rebilece\u011finiz DMD genindeki ekzonlarda delesyonlar bulunan hastalar i\u00e7in \u00f6zel olarak tasarlanm\u0131\u015ft\u0131r. Bu delesyonlar ekzon 51 atlamaya uygundur, \u00e7\u00fcnk\u00fc bu ekzonun atlanmas\u0131 genin okuma \u00e7er\u00e7evesini geri y\u00fckler ve bu da k\u0131salt\u0131lm\u0131\u015f ancak i\u015flevsel bir distrofin proteininin \u00fcretilmesiyle sonu\u00e7lan\u0131r.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"847\" height=\"1024\" src=\"https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/03\/amenable-to-exon-51-skipping-847x1024.jpg\" alt=\"Duchenne Musk\u00fcler Distrofisi \u0130\u00e7in Ekzon 51 Atlama Terapilerine Uygun Mutasyonlar ve Delesyonlar\" class=\"wp-image-4526\" title=\"\" srcset=\"https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/03\/amenable-to-exon-51-skipping-847x1024.jpg 847w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/03\/amenable-to-exon-51-skipping-248x300.jpg 248w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/03\/amenable-to-exon-51-skipping-768x929.jpg 768w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/03\/amenable-to-exon-51-skipping-1270x1536.jpg 1270w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/03\/amenable-to-exon-51-skipping-1693x2048.jpg 1693w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/03\/amenable-to-exon-51-skipping-10x12.jpg 10w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/03\/amenable-to-exon-51-skipping-347x420.jpg 347w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/03\/amenable-to-exon-51-skipping-150x181.jpg 150w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/03\/amenable-to-exon-51-skipping-300x363.jpg 300w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/03\/amenable-to-exon-51-skipping-696x842.jpg 696w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/03\/amenable-to-exon-51-skipping-1068x1292.jpg 1068w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/03\/amenable-to-exon-51-skipping-1920x2323.jpg 1920w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/03\/amenable-to-exon-51-skipping.jpg 1984w\" sizes=\"auto, (max-width: 847px) 100vw, 847px\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Ara\u015ft\u0131rmalar, DMD hastalar\u0131n\u0131n \u00f6nemli bir k\u0131sm\u0131n\u0131n (yakla\u015f\u0131k 13-15%) ekzon 51 atlamaya uygun delesyonlara sahip oldu\u011funu g\u00f6stermi\u015ftir. Bu delesyonlar tipik olarak DMD geninin kritik bir b\u00f6l\u00fcm\u00fcn\u00fc etkileyerek distrofin i\u015flevselli\u011finin kayb\u0131na neden olur. Ekzon 51 atlanarak, bu hastalar potansiyel olarak kas b\u00fct\u00fcnl\u00fc\u011f\u00fcn\u00fc koruyabilen, hastal\u0131\u011f\u0131n ilerlemesini yava\u015flatabilen ve ya\u015fam kalitesini iyile\u015ftirebilen modifiye edilmi\u015f bir distrofin formu \u00fcretebilirler.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ekzon 51 atlaman\u0131n yaln\u0131zca belirli genetik mutasyonlar i\u00e7in etkili oldu\u011funu ve hastalar\u0131n ekzon 51 tabanl\u0131 tedaviler i\u00e7in uygun aday olup olmad\u0131klar\u0131n\u0131 belirlemek i\u00e7in genetik testlerden ge\u00e7meleri gerekti\u011fini belirtmek \u00f6nemlidir. Yeni nesil dizileme (NGS) ve gen dizileme teknolojileri, bu delesyonlar\u0131 tan\u0131mlamay\u0131 ve ekzon atlama tedavilerine uygunluklar\u0131n\u0131 de\u011ferlendirmeyi kolayla\u015ft\u0131rm\u0131\u015ft\u0131r.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"clinical-trials-for-exon-51-skipping-therapies\">Ekzon 51 Atlama Terapileri i\u00e7in Klinik Denemeler<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Ekzon 51 atlama terapileri DMD tedavisinde \u00f6nemli bir ilerlemeyi temsil etse de, birka\u00e7 zorluk devam etmektedir. Ekzon atlama terapilerinin uzun vadeli faydalar ve i\u015flevsel iyile\u015ftirmeler a\u00e7\u0131s\u0131ndan etkinli\u011fi hala incelenmektedir. Ek olarak, hasta tepkisi de\u011fi\u015fkenli\u011fi (distrofinin ne \u00f6l\u00e7\u00fcde \u00fcretildi\u011fi ve bunun i\u015flevsel iyile\u015ftirmelere nas\u0131l d\u00f6n\u00fc\u015ft\u00fc\u011f\u00fc dahil) devam eden bir zorluk olu\u015fturmaktad\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u0130\u015fte ekzon 51 atlama konusunda umut vadeden \u00e7al\u0131\u015fmalar:<\/strong><\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"dyne-therapeutics-dyne-251-exon-51\">Dyne Therapeutics \u2013 DYNE-251<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">DYNE-251, ekzon 51 atlamaya uygun DMD&#039;li ki\u015filer i\u00e7in Faz 1\/2 k\u00fcresel DELIVER klinik denemesinde de\u011ferlendirilen deneysel bir tedavi y\u00f6ntemidir. (Daha Fazlas\u0131n\u0131 Okuyun: <a href=\"https:\/\/dmdwarrior.com\/tr\/dyne-therapeutics-announces-phase-1-2-deliver-trial-of-dyne-251-in-duchenne-muscular-dystrophy\/\">DYNE-251<\/a>)<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"jiao-tong-university-le-051\">Jiao Tong \u00dcniversitesi \u2013 LE051<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">\u015eanghay Jiao Tong \u00dcniversitesi T\u0131p Fak\u00fcltesi, ekzon 51 atlamaya uygun DMD hastalar\u0131nda LE051&#039;in tek bir intraven\u00f6z inf\u00fczyonunun g\u00fcvenli\u011fini, tolere edilebilirli\u011fini ve etkinli\u011fini de\u011ferlendirmek \u00fczere bir klinik \u00e7al\u0131\u015fma duyurdu. (Daha Fazlas\u0131n\u0131 Okuyun: <a href=\"https:\/\/dmdwarrior.com\/tr\/shanghai-jiao-tong-university-school-of-medicine-begins-clinical-trials-of-le051-exon-51-skipping-therapy\/\">LE051<\/a>)<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"bio-marin-pharmaceutical-bmn-351\">BioMarin \u0130la\u00e7 \u2013 BMN 351<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">BMN 351, ekzon 51 uyumlu DMD&#039;li erkek \u00e7ocuklar i\u00e7in yeni nesil bir antisens oligon\u00fckleotid (ASO) tedavisidir. ASO&#039;lar, h\u00fccrelerin belirli proteinleri nas\u0131l \u00fcretti\u011fini etkileyen ila\u00e7lard\u0131r. Bir\u00e7ok farkl\u0131 genetik sa\u011fl\u0131k durumunu tedavi etmek i\u00e7in kullan\u0131lmaktad\u0131rlar. BMN 351, ara\u015ft\u0131rma a\u015famas\u0131ndaki bir ila\u00e7t\u0131r, yani insanlarda g\u00fcvenli ve etkili oldu\u011fu bulunmam\u0131\u015ft\u0131r ve klinik denemeler d\u0131\u015f\u0131nda kullan\u0131m\u0131 onaylanmam\u0131\u015ft\u0131r. (Daha Fazlas\u0131n\u0131 Okuyun: <a href=\"https:\/\/clinicaltrials.biomarin.com\/clinical-trial\/a-phase-1-2-study-to-assess-the-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-bmn-351-in-participants-with-duchenne-muscular-dystrophy\/\" target=\"_blank\" rel=\"noopener\">BMN351<\/a>)<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"entrada-therapeutics\">Entrada Therapeutics \u2013 G\u0130R\u0130\u015e-601-51<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Duchenne hastal\u0131\u011f\u0131yla ya\u015fayan ve ekzon 51 atlamaya yatk\u0131n ki\u015filerin potansiyel tedavisi i\u00e7in ara\u015ft\u0131rma a\u015famas\u0131nda olan bir tedavi olan ENTR-601-51, mRNA okuma \u00e7er\u00e7evesini geri kazand\u0131rma ve hafif\u00e7e k\u0131salm\u0131\u015f ancak hala i\u015flevsel olan distrofin proteininin translasyonuna izin verme potansiyeli a\u00e7\u0131s\u0131ndan de\u011ferlendiriliyor. (Daha Fazlas\u0131n\u0131 Okuyun: <a href=\"https:\/\/www.entradatx.com\/pipeline\" target=\"_blank\" rel=\"noopener\">ENTR-601-51<\/a>)<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"nippon-shinyaku-ns-051-ncnp-04\">Nippon Shinyaku \u2013 NS-051\/NCNP-04<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">DMD, distrofin proteininin eksikli\u011finden kaynaklanan ilerleyici bir kas erimesi hastal\u0131\u011f\u0131d\u0131r. \u0130skelet, kalp ve solunum kaslar\u0131nda g\u00fc\u00e7s\u00fczl\u00fc\u011fe yol a\u00e7ar. DMD&#039;ye neden olabilecek bir\u00e7ok genetik mutasyon t\u00fcr\u00fc vard\u0131r ve NS-051\/NCNP-04, ekzon 51 atlama tedavisine uygun, do\u011frulanm\u0131\u015f gen mutasyonlar\u0131 olan hastalar\u0131 tedavi etmek i\u00e7in geli\u015ftirilmektedir. Devam\u0131n\u0131 Oku: <a href=\"https:\/\/dmdwarrior.com\/tr\/fda-grants-orphan-drug-designation-to-ns-051-ncnp-04-for-the-treatment-of-duchenne-muscular-dystrophy\/\">FDA, NS-051\/NCNP-04&#039;e Yetim \u0130la\u00e7 Tan\u0131m\u0131 Veriyor<\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"conclusion\">Sonu\u00e7<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Ekzon 51 atlama terapileri, DMD i\u00e7in umut vadeden bir tedavi yakla\u015f\u0131m\u0131 sunar ve bu tekni\u011fe uygun spesifik mutasyonlara sahip hastalar i\u00e7in umut sunar. Uzun vadeli i\u015flevsel faydalar hala ara\u015ft\u0131r\u0131l\u0131rken, ekzon 51 atlama terapileri Duchenne kas distrofisine kar\u015f\u0131 m\u00fccadelede heyecan verici bir ad\u0131m ileriyi i\u015faret ediyor.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Devam eden ara\u015ft\u0131rmalar, uzun vadeli klinik deneyler ve genetik testler ile ki\u015fiselle\u015ftirilmi\u015f t\u0131p alan\u0131ndaki ilerlemeler, bu tedavilerin optimize edilmesi ve gelecekte daha fazla DMD hastas\u0131na yayg\u0131nla\u015ft\u0131r\u0131lmas\u0131nda kritik \u00f6neme sahip olacakt\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Devam\u0131n\u0131 oku<\/strong>:\u00a0<a href=\"https:\/\/dmdwarrior.com\/tr\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Duchenne \u0130\u00e7in Klinik Ara\u015ft\u0131rmalar (T\u00fcm Ara\u015ft\u0131rmalar\u0131n Listesi)<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Duchenne Exon 51 skipping therapies are innovative treatments aimed at addressing the genetic mutation responsible for Duchenne muscular dystrophy (DMD). By skipping exon 51 in the dystrophin gene, these therapies help produce a shorter, functional version of the dystrophin protein, potentially slowing disease progression and improving quality of life for patients. This cutting-edge approach offers [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3444,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[122,193,194,77,178],"class_list":["post-3429","post","type-post","status-publish","format-standard","has-post-thumbnail","category-research","tag-exon-51","tag-exon-51-skipping","tag-exon-51-treatment","tag-exon-skipping","tag-exon-skipping-therapies"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/3429","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=3429"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/3429\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/3444"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=3429"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=3429"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=3429"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}